Business
Half-Year Report
Half-Year Report.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n \n Sareum Holdings PLC\n \n \n (\"Sareum\" or the \"Company\")\n \n \n Half-Year Report for the Six Months Ended 31 December 2022\n \n \n \n Cambridge, UK, 22 March 2023\n \n - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces its unaudited results for the six months ended 31 December 2022.\n \n \n Sareum also provides a broader update on its operational activities and pipeline progress.\n \n \n The Company will hold a virtual presentation for all existing and potential investors today, 22 March at 12:30 GMT, via the Investor Meet Company platform. Please click the following link to register to attend:\n \n \n https://www.investormeetcompany.com/sareum-holdings-plc/register-investor\n \n \n .\n \n \n \n OPERATIONAL HIGHLIGHTS -\n \n \n INCLUDING POST-PERIOD UPDATES\n \n \n \n \n SDC-1801 (autoimmune disease)\n \n \n \n SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.\n \n \n ·\n After the period end, Sareum submitted\n an application\n to perform Phase 1 clinical studies on SDC-1801 in Australia under the Clinical Trial Notification (CTN) scheme.\n \n \n ·\n Approval by the Human Research Ethics Committee (HREC) and acceptance of the CTN by Australia's medicines regulator, the Therapeutic Goods Administration (TGA), is expected in Q2 2023. Subject to this approval, Sareum plans to start the trial as soon as possible.\n \n \n ·\n Preparatory work for the trial is complete, including synthesis of the\n SDC-1801 drug substance under GMP conditions and GMP-compliant manufacturing of the SDC-1801 capsules.\n \n \n \n SDC-1802 (cancer immunotherapy)\n \n \n \n SDC-1802\n is a TYK2/JAK1\n inhibitor being developed for cancer immunotherapy.\n \n \n ·\n Sareum continues to work on the translational studies needed to\n support development of SDC-1802,\n defining the optimal cancer application prior to completing toxicology and manufacturing studies.\n \n \n ·\n Expertise and experience gained through SDC-1801 will support Sareum in optimising its planning and maintaining cost discipline.\n \n \n \n SRA737 (cancer)\n \n \n \n SRA737 is a clinical-stage oral, selective Checkpoint kinase 1 inhibit...